Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy

Author： Seo Takayuki   Nagata Rie   Ishitsu Takateru   Murata Tsukasa   Takaishi Chisato   Hori Masaharu   Nakagawa Kazuko  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.9, Iss.5, 2008-05, pp. : 527-537

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Polymorphisms of CYP2C19 and CYP2D6 in Israeli Ethnic Groups

By Huai-Rong Luo  

American Journal of PharmacoGenomics, Vol. 4, Iss. 6, 2004-01 ,pp. : 395-401

Adis International

Access to resources Recommend Favorite

Cytochrome P450 2C19 (CYP2C19) genotype appears to affect the efficacy of omeprazole

By  

Inpharma, Vol. 1, Iss. 1221, 2000-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

A Pharmacokinetic-Pharmacodynamic Model for Predicting the Impact of CYP2C9 and VKORC1 Polymorphisms on Fluindione and Acenocoumarol During Induction Therapy

By Verstuyft Céline   Delavenne Xavier  

Clinical Pharmacokinetics, Vol. 51, Iss. 1, 2012-01 ,pp. : 41-53

Adis International

Access to resources Recommend Favorite

Pharmacogenetic Prediction of Individual Variability in Drug Response Based on CYP2D6, CYP2C9 and CYP2C19 Genetic Polymorphisms

By  

Current Drug Metabolism, Vol. 15, Iss. 7, 2014-09 ,pp. : 711-718

Bentham Science Publishers

Access to resources Recommend Favorite

Impact of CYP2C8 and 2C9 polymorphisms on coronary artery disease and myocardial infarction in the LURIC cohort

By Haschke-Becher Elisabeth   Kirchheiner Julia   Trummer Olivia   Grünbacher Gerda   Kainz Alexander   Boehm Bernhard O   März Winfried   Renner Wilfried  

Pharmacogenomics, Vol. 11, Iss. 10, 2010-10 ,pp. : 1359-1365

Future Medicine

Access to resources Recommend Favorite